Keyphrases
Therapeutic Strategies
100%
JAK Inhibitors
100%
Philadelphia-negative Myeloproliferative Neoplasms
100%
Myeloproliferative Neoplasms
66%
Monotherapy
66%
Clinical Setting
33%
Novel Therapeutics
33%
Targeted Therapeutics
33%
Splenomegaly
33%
Disease Burden
33%
Disease Process
33%
Disease-modifying Therapy
33%
Natural History
33%
Medicine and Dentistry
Myeloproliferative Neoplasm
100%
Janus Kinase Inhibitor
75%
Diseases
50%
Monotherapy
50%
Disease Process
25%
Splenomegaly
25%
Targeted Therapeutic Agent
25%
Pharmacology, Toxicology and Pharmaceutical Science
Myeloproliferative Neoplasm
100%
Disease
75%
Janus Kinase Inhibitor
75%
Monotherapy
50%
Splenomegaly
25%
Biochemistry, Genetics and Molecular Biology
Janus Kinase Inhibitor
100%
Disease Burden
33%